Tenderwize
Retour à la recherche

Open-house rebate agreement for testosterone injection solution

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 03, 2027 · 430 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Testosteron in der Darreichungsform Injektionslösung, ATC G03BA03

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice repeatedly states that the arrangement is an open-house model and not a normal procurement procedure, which...

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive rebate agreements for pharmaceutical products concerning testosterone in injection solution form, ATC G03BA03.
  • Open-house model with identical, non-negotiable contract terms for all qualifying pharmaceutical companies.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement by AOK Bayern for testosterone injection solution (ATC G03BA03), not a competitive award procedure in the usual sense. The buyer states that it will conclude identical, non-exclusive rebate agreements with all interested pharmaceutical companies that meet the stated suitability requirement. Contracting is possible from 2026-01-01 until 2027-11-03, with contracts ending on 2027-12-31. Submission is via DTVP electronic portal with qualified electronic signature or by signed paper originals in duplicate; German language is required, and non-German documents need German translation.

Risques

The notice repeatedly states that the arrangement is an open-house model and not a normal procurement procedure, which...

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The signed contract and the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for testosterone injection solution

Single lot covering non-exclusive open-house rebate agreements for the medicinal product testosterone in injection solution form, ATC G03BA03. The notice says the contract terms are fixed and not individually negotiable. Place of performance is Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Dec 2025 - Dec 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 03, 2027

Détails de la procédure

Date de publication
16 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
759950-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30